Calcified Tissue International

, Volume 71, Issue 2, pp 103–111

The Efficacy and Tolerability of Risedronate Once a week for the Treatment of Postmenopausal Osteoporosis

Authors

  • J.P. Brown
    • Le Centre de recherche du CHUL, Laval University, Sainte-Foy, Québec, Canada
  • D.L. Kendler
    • Providence Health Care Centre, Vancouver, British Columbia, Canada
  • M.R. McClung
    • Osteoporosis Research Center, Portland, Oregon, USA
  • R.D. Emkey
    • Reading Hospital and Medical Center, Reading, Pennsylvania, USA
  • J.D. Adachi
    • Department of Medicine, St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada
  • M.A. Bolognese
    • Bethesda Health Research, Bethesda, Maryland, USA
  • Z. Li
    • Procter & Gamble Pharmaceuticals, Mason, Ohio, USA
  • A. Balske
    • Procter & Gamble Pharmaceuticals, Mason, Ohio, USA
  • R. Lindsay
    • Regional Bone Center, Helen Hayes Hospital, West Haverstraw, New York, USA
Article

DOI: 10.1007/s00223-002-2011-8

Cite this article as:
Brown, J., Kendler, D., McClung, M. et al. Calcif Tissue Int (2002) 71: 103. doi:10.1007/s00223-002-2011-8
Download to read the full article text

Copyright information

© Springer-Verlag New York Inc. 2002